BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 10807761)

  • 1. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis.
    Teede HJ; McGrath BP; Smolich JJ; Malan E; Kotsopoulos D; Liang YL; Peverill RE
    Arterioscler Thromb Vasc Biol; 2000 May; 20(5):1404-9. PubMed ID: 10807761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
    Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
    Vehkavaara S; Silveira A; Hakala-Ala-Pietilä T; Virkamäki A; Hovatta O; Hamsten A; Taskinen MR; Yki-Järvinen H
    Thromb Haemost; 2001 Apr; 85(4):619-25. PubMed ID: 11341495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, placebo-controlled trial of the effects of continuous combined hormone replacement therapy on coagulation and fibrinolytic systems in healthy postmenopausal women.
    Salobir BG; Keber I; Vrabic L
    Fertil Steril; 2002 Dec; 78(6):1178-83. PubMed ID: 12477508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial.
    Hemelaar M; Kenemans P; Hack CE; Klipping C; van der Mooren MJ
    Menopause; 2008; 15(2):248-55. PubMed ID: 17693902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial.
    Scarabin PY; Alhenc-Gelas M; Plu-Bureau G; Taisne P; Agher R; Aiach M
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):3071-8. PubMed ID: 9409295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers.
    Stevenson JC; Oladipo A; Manassiev N; Whitehead MI; Guilford S; Proudler AJ
    Br J Haematol; 2004 Mar; 124(6):802-8. PubMed ID: 15009069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose oral combination of 17beta-estradiol and norethisterone acetate in postmenopausal women decreases factor VII, fibrinogen, antithrombin and plasminogen activator inhibitor-1.
    Borgfeldt C; Li C; Samsioe G
    Climacteric; 2004 Mar; 7(1):78-85. PubMed ID: 15259286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: a randomized, placebo-controlled study.
    Perera M; Sattar N; Petrie JR; Hillier C; Small M; Connell JM; Lowe GD; Lumsden MA
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1140-3. PubMed ID: 11238498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of waist and hip circumference with coagulation and fibrinolysis in postmenopausal women.
    Peverill RE; Teede HJ; Malan E; Kotsopoulos D; Smolich JJ; McGrath BP
    Clin Sci (Lond); 2007 Nov; 113(9):383-91. PubMed ID: 17608627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomized study.
    Winkler UH; Altkemper R; Kwee B; Helmond FA; Coelingh Bennink HJ
    Fertil Steril; 2000 Jul; 74(1):10-9. PubMed ID: 10899490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism--results from a randomized, double-blind, clinical trial.
    Høibraaten E; Qvigstad E; Andersen TO; Mowinckel MC; Sandset PM
    Thromb Haemost; 2001 May; 85(5):775-81. PubMed ID: 11372667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipids and clotting factors during low dose transdermal estradiol/norethisterone use.
    Brynhildsen J; Hammar M
    Maturitas; 2005 Apr; 50(4):344-52. PubMed ID: 15780536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis.
    Zegura B; Keber I; Sebestjen M; Koenig W
    Atherosclerosis; 2003 May; 168(1):123-9. PubMed ID: 12732395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haemostatic activation in post-menopausal women taking low-dose hormone therapy: less effect with transdermal administration?
    Brosnan JF; Sheppard BL; Norris LA
    Thromb Haemost; 2007 Apr; 97(4):558-65. PubMed ID: 17393018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women.
    Koh KK; Mincemoyer R; Bui MN; Csako G; Pucino F; Guetta V; Waclawiw M; Cannon RO
    N Engl J Med; 1997 Mar; 336(10):683-90. PubMed ID: 9041098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of hormone replacement therapy on coagulation and fibrinolysis in postmenopausal women.
    Koh KK
    Int J Hematol; 2002 Aug; 76 Suppl 2():44-6. PubMed ID: 12430899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of 17 beta-oestradiol on variables of coagulation and fibrinolysis in postmenopausal women with type 2 diabetes mellitus.
    Brussaard HE; Leuven JA; Krans HM; Kluft C
    Vascul Pharmacol; 2002 Aug; 39(3):141-7. PubMed ID: 12616982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pulsed estrogen therapy on hemostatic markers in comparison with oral estrogen regimen in postmenopausal women.
    Basurto L; Saucedo R; Zárate A; Martínez C; Gaminio E; Reyes E; Hernandez M
    Gynecol Obstet Invest; 2006; 61(2):61-4. PubMed ID: 16192735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind, randomized, placebo controlled study on the effects of the monophasic oral contraceptive containing 30 micrograms ethinyl estradiol and 2.00 mg dienogest on the hemostatic system.
    Spona J; Feichtinger W; Kindermann C; Schneider B; Mellinger U; Walter F; Moore C; Gräser T
    Contraception; 1997 Aug; 56(2):67-75. PubMed ID: 9315414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.